Chitosan hydrogel for localized gene silencing

Cancer Biology and Therapy

Volumn 11, Issue 9, 2011, Pages 839-845

  Han, Hee Dong ^a   Mora, Edna M ^a,b,c   Roh, Ju Won ^a,d   Nishimura, Masato ^a   Lee, Sun Joo ^a,e   Stone, Rebecca L ^a   Bar Eli, Menashe ^a   Lopez Berestein, Gabriel ^a   Sood, Anil K ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF PUERTO RICO SCHOOL OF MEDICINE   (Puerto Rico)

^c UNIVERSITY OF PUERTO RICO   (Puerto Rico)

^d Dongguk University   (South Korea)

^e Konkuk University Hospital   (South Korea)

Author keywords

Chitosan; Hydrogel; Local delivery; RNA interference

Indexed keywords

CHITOSAN DERIVATIVE; SMALL INTERFERING RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST TUMOR; CANCER INHIBITION; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; FLUORESCENCE MICROSCOPY; GENE SILENCING; HYDROGEL; IN VIVO STUDY; MELANOMA; MOUSE; NONHUMAN; PHASE TRANSITION; TARGET CELL;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; CHITOSAN; DRUG DELIVERY SYSTEMS; FEMALE; GENE SILENCING; HUMANS; HYDROGELS; MELANOMA; MICE; MICE, NUDE; RNA, SMALL INTERFERING; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79955504557     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.11.9.15185     Document Type: Article

References (21)

1. Aagaard L, Rossi JJ. RNAi therapeutics: principles, prospects and challenges. Adv Drug Deliv Rev 2007; 59:75-86. (Pubitemid 46770900)
2. Merritt WM, Lin YG, Han LY, Kamat AA, Spannuth WA, Schmandt R, et al. Dicer, Drosha and outcomes in patients with ovarian cancer. N Engl J Med 2008; 359:2641-50.
3. Whitehead KA, Langer R, Anderson DG. Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov 2009; 8:129-38.
4. Thaker PH, Han LY, Kamat AA, Arevalo JM, Takahashi R, Lu C, et al. Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nat Med 2006; 12:939-44. (Pubitemid 44175146)
5. Walter KA, Tamargo RJ, Olivi A, Burger PC, Brem H. Intratumoral chemotherapy. Neurosurgery 1995; 37:1128-45.
6. Han HD, Song CK, Park YS, Noh KH, Kim JH, Hwang T, et al. A chitosan hydrogel-based cancer drug delivery system exhibits synergistic antitumor effects by combining with a vaccinia viral vaccine. Int J Pharm 2008; 350:27-34. (Pubitemid 351146677)
7. + T cell-mediated anti-tumor immunity. Clin Exp Metastasis 2009; 26:179-87.
8. Willmott LJ, Monk BJ. Cervical cancer therapy: current, future and anti-angiogensis targeted treatment. Expert Rev Anticancer Ther 2009; 9:895-903.
9. Johannsen A, Tellefsen M, Wikesjo U, Johannsen G. Local delivery of hyaluronan as an adjunct to scaling and root planing in the treatment of chronic periodontitis. J Periodontol 2009; 80:1493-7.
10. Hwang JY, Mangala LS, Fok JY, Lin YG, Merritt WM, Spannuth WA, et al. Clinical and biological significance of tissue transglutaminase in ovarian carcinoma. Cancer Res 2008; 68:5849-58.
11. Fok JY, Ekmekcioglu S, Mehta K. Implications of tissue transglutaminase expression in malignant melanoma. Mol Cancer Ther 2006; 5:1493-503. (Pubitemid 44070486)
12. Mangala LS, Fok JY, Zorrilla-Calancha IR, Verma A, Mehta K. Tissue transglutaminase expression promotes cell attachment, invasion and survival in breast cancer cells. Oncogene 2007; 26:2459-70. (Pubitemid 46597265)
13. Verma A, Wang H, Manavathi B, Fok JY, Mann AP, Kumar R, et al. Increased expression of tissue transglutaminase in pancreatic ductal adenocarcinoma and its implications in drug resistance and metastasis. Cancer Res 2006; 66:10525-33. (Pubitemid 44799775)
14. Varghese OP, Sun W, Hilborn J, Ossipov DA. In situ cross-linkable high molecular weight hyaluronan-bisphosphonate conjugate for localized delivery and cell-specific targeting: a hydrogel linked prodrug approach. J Am Chem Soc 2009; 131:8781-3.
15. Krebs MD, Jeon O, Alsberg E. Localized and sustained delivery of silencing RNA from macroscopic biopolymer hydrogels. J Am Chem Soc 2009; 131:9204-6.
16. Singh A, Suri S, Roy K. In-situ crosslinking hydrogels for combinatorial delivery of chemokines and siRNA-DNA carrying microparticles to dendritic cells. Biomaterials 2009; 30:5187-200.
17. Han HD, Nam DE, Seo DH, Kim TW, Shin BC, Choi HS. Preparation and biodegradation of thermosensitive chitosan hydrogel as a function of pH and temperature. Macromol Res 2004; 12:507-11.
18. Landen CN Jr, Chavez-Reyes A, Bucana C, Schmandt R, Deavers MT, Lopez-Berestein G, et al. Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res 2005; 65:6910-8. (Pubitemid 41060730)
19. Scott J, Dorr RT, Samulitis B, Landowski TH. Imexon-based combination chemotherapy in A375 human melanoma and RPMI 8226 human myeloma cell lines. Cancer Chemother Pharmacol 2007; 59:749-57. (Pubitemid 46440597)
20. Mangala LS, Zuzel V, Schmandt R, Leshane ES, Halder JB, Armaiz-Pena GN, et al. Therapeutic Targeting of ATP7B in Ovarian Carcinoma. Clin Cancer Res 2009; 15:3770-80.
21. Lee JW, Han HD, Shahzad MM, Kim SW, Mangala LS, Nick AM, et al. EphA2 immunoconjugate as molecularly targeted chemotherapy for ovarian carcinoma. J Natl Cancer Inst 2009; 101:1193-205.